New conference: Translational cancer research - Integration of basic and clinical perspectives
We are excited to announce this excellent opportunity to connect with a vibrant community of scientists from both basic and clinical perspectives and to engage in meaningful discussions. The Translational Cancer Research Conference will focus on integrating basic and clinical cancer research, exploring how to bridge the gaps between them, and presenting talks by leading international experts in basic and translational cancer research.
We hope to see you on 25 February 2026 at the Danish Architecture Centre in Copenhagen.
Conference registration
The conference opens for registration on 8 October 2025.
Call for Abstracts: Now Open
We invite all interested researchers to submit abstracts on research projects, clinical trials or other research activities within the area of translational cancer research. Submitted abstracts can be considered for oral presentations – as talks of 10 minutes or speed talks of 4 minutes.
Your abstract should highlight the core aspects of your research in up to 300 words. The organizing committee will use the abstract to assess the relevance and quality of your submission. It should be clear, concise, and sufficiently detailed to stand on its own.
The text must include: Background, purpose, method, collaborators and results.
The abstract is submitted by a lead author on behalf of a group and the author list should therefore include both basic and clinical researchers.
Your abstract must be submitted to dccc.info@dccc.dk no later than 26 November, 2025 at 12 noon.
Abstracts will only be published for the conference participants.
Preliminary programme of the conference
Arrival and breakfast at 9:15 AM
Welcome (the programme starts at 9:45 AM)
Session 1: Integration of basic and clinical perspectives
Epigenetics
Anja Groth, Professor, Group leader, Epigenome Replication and Maintenance, Danish Cancer Institute and Kirsten Grønbæk, Professor, Department of Haematology, Rigshospitalet
Rare cancers
Ninna Aggerholm Pedersen, Clinical Associate Professor, MD, Dep. Of Oncology, Aarhus University hospital/ Department of Clinical Research and Birgitte Sandfeld-Paulsen, MD PhD, Head of Department, Department of Clinical Biochemistry, Aalborg University Hospital
Renalcancer
Niels Fristrup, MD, PhD, Consultant & Assoc. Professor, Dept. of Clinical Oncology, Aarhus University Hospital, DaRenCa and Iben Lyskjær Heimann Associate Professor, PhD, Group leader, Department of Molecular Medicine, Aarhus University
Mechanisms of cancer drug resistance
Henrik Ditzel, MD, Professor, Consultant, Head of Department of Molecular Medicine, Cancer and Inflammation Research, University of Southern Denmark and Marianne Vogsen, MD, PhD, Associate professor, Department of Oncology, Odense University Hospital
Biologically guided radiation therapy
Mikael Palner, Associate Professor / Head of Preclinical Imaging Core Facility, University of Southern Denmark and Faisal Mahmood, Professor, Research unit of Oncology, Odense University Hospital and Department of Clinical Research
From Discovery to First-in-Human: Translating ADC Innovation into Clinical Trials
Lars Engelholm, Group Leader, Associate Professor, Finsen Laboratory, Rigshospitalet and clinical co speaker TBD
Lunch and networking
Session 2: How to organize cancer research and bridging the gaps -
a continuum from research discoveries to clinical application
Title of presentation tbd
Kristian Helin, Professor, Chief Executive and President of The Institute of Cancer Research, London
Preclinical animal models in cancer therapy
Martin Roelsgaard Jakobsen, Professor, Department of Biomedicine, Aarhus University
Additional speakers will be announced in the session.
Session 3: International block - Leading basic and translational cancer research
Innovative team science – from laboratory discoveries to cancer treatments (title tbd)
Peter Jones, Chief Scientific Officer, Ph.D., D.Sc., Van Andel Institute, American Association for Cancer Research
Additional speakers will be announced in the session.
Coffee break and networking
Session 4: Flash talks – based on submitted abstracts
We invite all interested researchers to submit abstracts on research projects, clinical trials or other research activities within the area of translational cancer research. Submitted abstracts can be considered for oral presentations – as talks of 10 minutes or speed talks of 4 minutes.
Networking and dinner (Provisional finishing time 19:30)
Why DCCC has chosen to work with integration of basic and clinical cancer research
It is DCCC’s ambition to explore how the connection and integration between basic and clinical cancer research can be strengthened, and to support the implementation of more translational studies. It is essential that advances and breakthroughs in research – both in the laboratory and through new medicine and technological solutions – are translated into clinical practice.
To take the first steps, DCCC invites all researchers within the area of translational cancer research to a national conference focusing on the integration of basic and clinical cancer research. The ambition of the conference is also to take the first steps towards increasing visibility across the various local initiatives and translational cancer research environments. As the working language within translational cancer research is English, the conference will be conducted in English.
